Woodline Partners’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.1M | Buy |
1,100,657
+295,500
| +37% | +$5.93M | 0.12% | 259 |
|
|
2025
Q1 | $15.8M | Sell |
805,157
-765
| -0.1% | -$15.1K | 0.1% | 266 |
|
|
2024
Q4 | $18.1M | Sell |
805,922
-265
| -0% | -$5.96K | 0.12% | 226 |
|
|
2024
Q3 | $20.6M | Buy |
806,187
+83,683
| +12% | +$2.14M | 0.17% | 188 |
|
|
2024
Q2 | $16.9M | Buy |
722,504
+326,818
| +83% | +$7.64M | 0.16% | 187 |
|
|
2024
Q1 | $6.96M | Hold |
395,686
| – | – | 0.06% | 320 |
|
|
2023
Q4 | $5.48M | Hold |
395,686
| – | – | 0.06% | 306 |
|
|
2023
Q3 | $5.41M | Buy |
+395,686
| New | +$5.41M | 0.06% | 304 |
|
|
2023
Q1 | – | Sell |
-216,601
| Closed | -$3.54M | – | 675 |
|
|
2022
Q4 | $3.54M | Hold |
216,601
| – | – | 0.05% | 372 |
|
|
2022
Q3 | $1.98M | Sell |
216,601
-21,222
| -9% | -$194K | 0.03% | 460 |
|
|
2022
Q2 | $1.16M | Sell |
237,823
-18,431
| -7% | -$90K | 0.02% | 500 |
|
|
2022
Q1 | $1.93M | Buy |
256,254
+183,645
| +253% | +$1.38M | 0.03% | 396 |
|
|
2021
Q4 | $653K | Buy |
72,609
+39,068
| +116% | +$351K | 0.01% | 539 |
|
|
2021
Q3 | $547K | Buy |
+33,541
| New | +$547K | 0.01% | 542 |
|